Abstract
Patients undergoing HCT (mainly allo-HCT) have a risk of developing complications related to pre-, peri-, and post-HCT. The resulting morbidity of the HCT process makes it necessary for patients to adopt a healthy lifestyle that promotes health and contemplate preventive measures for the detection and treatment of possible complications.
You have full access to this open access chapter, Download chapter PDF
1 Introduction
Patients undergoing HCT (mainly allo-HCT) have a risk of developing complications related to pre-, peri-, and post-HCT. The resulting morbidity of the HCT process makes it necessary for patients to adopt a healthy lifestyle that promotes health and contemplate preventive measures for the detection and treatment of possible complications.
The short- and long-term controls allow for regular and systematic screening and at the same time are an opportunity to give advice on healthy lifestyle habits. Monitoring should be multidisciplinary with involvement of hematology, other medical specialties, physicians of primary care, nursing, and mental health professionals.
Early and late complications, as well as psychological problems, are discussed in Parts IV, V, and VI of the Handbook.
After discharge, a long-term follow-up plan for each patient is needed which takes the given treatment and individual risk factors into account.
The recommendations related to screening and prevention post-HCT can be consulted in several web pages (see References).
2 Monitoring Depending on the Type of HCT
2.1 Autologous HCT
Timing | Monitoring |
---|---|
From discharge to day +100 | Until full hematologic recovery, it is recommended to live near the hospital Recommended controlsa: – Clinical evaluation and transfusions when necessary – Basic hematological and biochemical tests – Specific markers for different diseases |
At +3 months | Evaluate the status of the primary disease Recommended controlsa: – Hematological and biochemical tests, specific tumoral markers – MRD evaluation: Immunophenotype and molecular specific adapted to each disease – BM biopsy in case of NHL, HL, MPS, and solid neoplasms with previous marrow affectation, in the remaining disease BM smears (see specific chapters) – Imaging tests depending on primary disease |
Long term | Visits every 6 months up to 2 years and then annually Recommended controlsa: – Analytical and complementary explorations: See Table 22.1 – Baseline disease: Control of possible progression or relapse during at least 5 years – In patients treated with chemotherapy + radiotherapy, assess the risk of second malignancies or MDS after HCT |
2.2 Allogeneic HCT
Timing | Monitoring |
---|---|
From discharge to day +100 | It is recommended that the patient resides near the transplant center during the first 3–6 months after HCT Recommended controlsa: – Weekly clinical evaluation, during the first month, every other week until second month, every 2 weeks until third month, and then monthly up to 6–12 m, unless problems arise. It must include complete physical examination, with special emphasis on data of acute GvHD, infections, and pulmonary complications – Blood samples: Complete blood count, liver and kidney function, Mg, levels of IS agents, quantify CMV by PCR (and EBV if ATG); chimerism evaluation at 1 and 2 month – BM aspirate (or biopsy) in diseases with previous marrow affectation (usually within 1 month of HCT) |
At 3 months | Usually, this moment marks the turning point so that, if the patient does not have major problems, he/she can be monitored by the referring doctor. However, the patient should be periodically reevaluated at the transplant center (every 3–4 months during the first year, every 4–6 months during the second year, and annually after the third year) Recommended controlsa: – Visit and complete physical exploration with special emphasis on the signs of acute and chronic GvHD (assessment by organs as indicated in Chaps. 43 and 44 and paragraph 22.3) – Blood test: Complete blood count, kidney function, liver function, clearance creatinine, IS levels; chimerism and sample for MRD follow-up. In patients aged <17 years, weight and height every 3 months |
Long term | It depends on the complications that arise during follow-up. If there are no complications, it is recommended that a patient visits to the center every 6 months up to 3 years and annually thereafter Recommended controls: – Visit and complete physical examination including gynecological evaluation and endocrinological, if appropriate – Analytical and complementary explorations: See sect. 22.3 – Specific controls: Specific MRD studies on diseases with markers (see corresponding chapters) – In patients treated with chemotherapy + radiotherapy, the risk of secondary neoplasms |
3 Organ-Specific Long-Term Monitoring
Table 22.1 analyzes organ by organ the long-term follow-up recommendations.
4 Fertility (See Chap. 56)
5 Quality of Life (See Chap. 34)
Key Points
-
Patients auto- and mainly allo-HCT have a risk of developing complications related to pre-, peri-, and post-HCT.
-
The resulting morbidity of the HCT process makes it necessary for patients to adopt a healthy lifestyle that promotes health and contemplate preventive measures for the detection and treatment of possible complications.
-
The short- and long-term controls allow for regular and systematic screening and at the same time are an opportunity to give advice on healthy lifestyle habits. These recommendations can be based on comorbidity and individual risk factors.
-
Monitoring should be multidisciplinary with involvement of hematology, other medical specialties, physicians of primary care, nursing, and mental health professionals.
References
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:348–71.
Recommended References
DeFilipp Z, Duarte RF, Snowden JA, et al. Metabolic syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the CIBMTR and EBMT. Biol Blood Marrow Transplant. 2016;22:1493–503.
Dietz AC, Mehta PA, Vlachos A, et al. Current knowledge and priorities for future research in late effects after hematopoietic cell transplantation for inherited bone marrow failure syndromes: consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017;23:726–35.
Dyer G, Gilroy N, Bradford J, et al. A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales. Australia Br J Haematol. 2016;172:592–601.
Elad S, Raber-Durlacher JE, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the EBMT. Support Care Cancer. 2015;23:223–36.
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance Version June 03, 2015. Long-Term Follow-Up After Hematopoietic Stem Cell Transplant General Guidelines For Referring Physicians.
Hashimi SK, Bredeson C, Duarte RF, et al. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative. The healthcare Delivery Working group report. Biol Blood Marrow Transplant. 2017;23:717–25.
Heimall J, Buckley RH, Puck J, et al. Recommendations for screening and management of late effects in patients with severe combined immunodeficiency after allogenic hematopoietic cell transplantation: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2017;23:1229–40.
Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50:1013–23.
National Marrow Donor Program Guidelines, n.d.. www.BeTheMatch.org/md-guidelines. For patients: www.BeTheMatch.org/Patient; For Pediatric patients: www.survivorshipguidelines.org.
Parsons SK, Tighiouart H, Terrin N. Assessment of health-related quality of life in pediatric hematopoietic stem cell transplant recipients: progress, challenges and future directions. Expert Rev Pharmacoecon Outcomes Res. 2013;13:217–25.
Persoon S, Kersten MJ, van der Weiden K, et al. Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:682–90.
Shenoy S, Gaziev J, Angelucci E, et al. Late effects screening guidelines after Hematopoietic Cell Transplantation (HCT) for hemoglobinopathy: consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant. 2018;24(7):1313–21.
Tichelli A, Rovó A. Survivorship after allogeneic transplantation-management recommendations for the primary care provider. Curr Hematol Malig Rep. 2015;10:35–44.
Tichelli A, Savani B, Hashmi SK, et al. Long-term follow-up program and transplant clinic setup. In: Savani B, Tichelli A, editors. Blood and marrow transplantation long term management. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2021a. p. 14–23.
Tichelli A, Savani B, Hashmi SK, et al. Long-term follow-up program and transplant clinic setup. In: Savani B, Tichelli A, editors. Blood and marrow transplantation long term management. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2021b. p. 32–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2024 The Author(s)
About this chapter
Cite this chapter
Suárez-Lledó, M., Rovira, M. (2024). Short- and Long-Term Controls After HCT. In: Sureda, A., Corbacioglu, S., Greco, R., Kröger, N., Carreras, E. (eds) The EBMT Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-44080-9_22
Download citation
DOI: https://doi.org/10.1007/978-3-031-44080-9_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-44079-3
Online ISBN: 978-3-031-44080-9
eBook Packages: MedicineMedicine (R0)